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2Tuberculosis (TB) is a challenging disease to diagnose, treat, and control globally and in the United 
States. TB is spread through the air from one person to another. TB bacteria are released into the air 
when a person with TB disease of the lungs or throat coughs, sneezes, speaks, or sings. People nearby 
may breathe in these bacteria and become infected.  
Globally, TB is one of the most common infectious diseases and the leading cause of death among 
people living with HIV (PLHIV).  In 2010, a total of 8.8 million people become sick with TB disease, most 
of whom (82%) live in one of the 22 high burden countries for TB.  While significant progress has been 
made toward the elimination of TB in the United States, this disease remains an urgent public health 
problem in many other parts of the world.  
TB in the United States reflects the global reality.   Latest surveillance data show the annual TB 
incidence rate among the U.S.-born was 1.6 per 100,000 compared to 18.1 in foreign-born individuals.  
In 2010, 60% of all TB cases and 88% of drug-resistant TB cases1 in the United States occurred among 
people born in other countries. More than 75% of these individuals were born in just 15 countries.  
Many of CDC’s global TB control activities are focused in these high-burden and origin countries.  
Investing in TB control in high-burden settings reduces TB cases in the United States, costs less than 
screening at U.S. entry points, and saves funds that would be spent treating TB disease in the U.S. 
Strong national TB programs, such as we have in the United States, strive to reduce the opportunity for 
TB transmission particularly during travel, immigration, work, or study abroad; however, these remain 
routes of transmission internationally. CDC collaborates with other U.S. Government (USG) agencies, 
presenting a unified front in working with other governments, multilateral organizations, and NGOs 
to implement The Global Plan to Stop TB, advancing new diagnostic, treatment, and programmatic 
strategies to fight TB worldwide.
1Drug-resistant TB is defined as TB that is resistant to any of the first-line drugs commonly 
used to treat TB.  Please see the CDC website for more information about drug-resistant TB: 
http://www.cdc.gov/tb/topic/drtb
TB in the United States: A Global Perspective
Percentage of TB Cases Among Foreign-born Persons, 
United States*
Since 1999, the proportion of TB cases among foreign-born 
individuals has risen  in nearly every state. More than half of all TB 
cases in 31 states were among foreign-born individuals in 2009.
Number of TB Cases in U.S.-born vs. 
Foreign-born Persons United States, 1993–2010*
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3Many USG agencies support international health programs.  In supporting international TB control 
programs, USG agencies play complementary roles to reduce duplication and leverage each agency’s 
strengths.  USG agencies are actively engaged in implementing international TB control plans, 
including support of the Global Plan to Stop TB, which seeks to halve TB prevalence and mortality 
by 2015.  USG agencies support this plan by assisting high-burden countries to expand basic TB 
control programs, invest in research and development initiatives, and build programs with a focus 
on reducing TB/HIV co-morbidity, preventing and treating multidrug-resistant TB, and reaching 
vulnerable populations.  
CDC plays an important role in finding the most effective ways to implement new tools and 
approaches in resource-limited and high-burden settings through clinical and operations research, 
technical assistance, program and policy design, demonstration projects, and program monitoring 
and evaluation.  CDC focuses on supporting innovative approaches to screening, diagnosing, 
case-finding, and curing TB to stop the spread 
of disease and prevent development of drug 
resistance.
CDC is particularly interested in finding new 
ways to prevent TB among people who are 
most vulnerable, including those co-infected 
with HIV, women, children, and those who 
are incarcerated, homeless, or experiencing 
substance or alcohol abuse.  CDC also helps 
national TB programs and communities 
develop and improve policies and strategies for 
conducting surveillance, upgrading laboratory 
systems, and training new researchers and 
outreach and health care workers.  CDC looks for 
ways to provide effective TB control in resource-
limited and high-burden settings by helping 
refine policies and build partnerships.  Lessons 
learned through overseas research are also used 
to inform U.S. domestic programs and policies.
CDC Partners in Global TB Control
CDC’s Role in the Effort to Control TB Globally
An outreach worker from CDC’s collaboration in Botswana 
educates clients about TB. (Photo Credit:  Mavis Bengtsson, 
BOTUSA).
Examples of other USG agencies’ work to control TB globally include:
• The National Institutes of Health’s (NIH) biomedical and clinical research and 
development for vaccines, diagnostic technologies, and better TB treatments; 
• The U.S. Agency for International Development’s (USAID) material support to 
country programs and partners to scale-up effective strategies; and
• The Office of the Global AIDS Coordinator’s (OGAC) coordination of global TB and 
HIV efforts.
2
42Multidrug-resistant TB (MDR TB) is defined as TB that is resistant to at least two of the best anti-
TB drugs, isoniazid and rifampicin. These drugs are considered first-line drugs and are used to 
treat all persons with susceptible TB disease.  For more information about MDR TB: 
http://www.cdc.gov/tb/publications/factsheets/drtb/MDRTB.pdf
       Map of ongoing collaborations 
between CDC and partner Ministries 
of Health: Botswana, Cambodia, 
China, Guyana, Ethiopia, Haiti, 
India, Kenya, Lesotho, Mexico, 
Mozambique, Peru, Philippines, 
Russia, Rwanda, South Africa, 
Thailand, and Vietnam
CDC’s Division of Tuberculosis Elimination’s (DTBE) 
Global TB Priorities
DTBE, along with other CDC programs and USG agencies, collaborates with national TB programs 
and international partners to control TB worldwide. DTBE’s international priorities include:
• Strengthening national TB programs in WHO-designated high-burden TB and multidrug-resistant 
TB (MDR TB)2  countries and countries that contribute to the TB burden in the United States; 
• Implementing the President’s Emergency Plan for AIDS Relief (PEPFAR) goals by reducing the 
impact of HIV and TB prevalence and mortality; 
• Improving and expanding the diagnosis, treatment, and prevention of drug-resistant TB 
internationally and among the foreign-born in the United States; 
• Strengthening TB laboratory systems to achieve high-quality lab performance; 
• Improving infection control (IC) practices to prevent TB transmission and provide a safer 
environment in congregate settings; and
• Supporting programmatically relevant research on the diagnosis, management, and 
prevention of TB infection and disease through the TB Trials Consortium.
DTBE has worked in nearly every region of the world, providing technical assistance and 
participating in research collaborations to improve TB control. Significant programmatic and research 
collaborations are ongoing in Botswana, Cambodia, China, India, Kenya, Mexico, Russia, South Africa, 
Thailand, and Vietnam.  
DTBE’s Select Accomplishments in Global TB control
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5Raising awareness at a rally.  Globally, TB is 
the leading cause of death among people 
living with HIV. (Photo Credit: Alex Miranda, 
UNAIDS)
Improving Diagnosis of TB in People Living with 
HIV (PLHIV): An Evidence-Based Screening and 
Diagnostic Approach
Prevention of TB Disease in PLHIV: Evaluating the 
Impact of Isoniazid Preventive Therapy (IPT)
DTBE led a cross-sectional study (Improving Diagnosis of TB in HIV-Infected Persons: The ID-TB/HIV 
Study), enrolling more than 2,000 PLHIV from eight anti-retroviral (ARV) clinics in Cambodia, Thailand, 
and Vietnam to determine the best method for screening and diagnosing TB in PLHIV. The study found 
that using previously recommended screening approaches failed to detect more than two-thirds of 
patients with TB disease. However, screening PLHIV for TB using a combination of three symptoms 
detected almost all cases (93%) among this population.  The presence of one or more symptom (cough, 
fever, or night sweats) is a positive symptoms screen, whereas absence of all symptoms is a negative 
symptom screen. Patients with a positive symptom screen need further evaluation to accurately 
diagnose TB disease. Patients with a negative symptom screen have TB disease reliably ruled-out (97% 
without TB had no symptoms), allowing isoniazid preventive therapy (IPT) to be started more quickly. 
In follow up to this study, DTBE and WHO collaborated on a meta-analysis which led to a change in 
WHO’s international guidelines for screening for TB among PLHIV.
The Isoniazid Prevention Therapy Trial (IPTT), conducted in 
Botswana from 2004 to 2011, was designed to determine 
whether 36 months of isoniazid treatment was more effective 
in preventing TB disease among PLHIV than the routinely 
prescribed six month treatment. The main finding was that 
while IPT was highly effective (>90% reduction) in reducing 
TB in people with a positive tuberculin skin test, 36 months 
of IPT further reduced the risk of developing TB disease by 
76% compared with six months of IPT for these people. CDC 
Botswana has worked closely with the National TB and HIV 
Programs, including providing cost effectiveness analysis to 
modify the National IPT Program based on these findings. The 
trial continues to monitor incident TB in those who received 
IPT. This study informed a change in WHO guidelines, now 
suggesting that PLHIV with a positive skin test should receive 
36 months of IPT. 4
Figure 1: The Best Evidence-Based Approach to Screening for 
TB Disease Among PLHIV
Asking patients about 
cough, fever, and night 
sweats detected 93% 
of PLHIV with TB in this 
study. Asking patients 
about cough alone de-
tected less than 33% of 
PLHIV with TB disease.
Ask patients if they have:
1. Cough of any duration;
2. Fever of any duration; and
3. Night sweats more than 3 times a week.
Patients answer yes to 
ANY symptom
Patients answers no to 
ALL symptoms
Further evaluate 
patient for TB disease
TB disease can be confidently 
ruled out. Patient can start 
Isoniazid preventive therapy 
(IPT), as appropriate.
97% of study 
participants who did 
not have cough, fever, 
or night sweats did not 
have TB disease.
63Second-line drugs (SLD) are used to treat MDR TB, but are more costly, less effective and have 
more side effects than first-line drugs used to treat susceptible TB.  MDR TB plus resistance to 
certain second-line drugs is considered extensively drug-resistant (XDR TB).  For more information: 
http://www.cdc.gov/tb/publications/factsheets/treatment.htm.
Training laboratorians on 
infection control procedures 
(Photo credit: Garry Blackwelder, CDC)
Preserving Effective TB Treatment for Second Line 
Drugs for Treatment of Drug-Resistant TB
In collaboration with the Ministry of Health (MOH) and local partners in nine countries, DTBE 
spearheaded the Preserving Effective TB Treatment Study (PETTS). PETTS has informed the new 
framework for WHO and international partners that support countries in achieving universal access 
to the diagnosis, treatment, and care of MDR TB. PETTS, a large multi-year, multi-country study 
compared programs approved by the Green Light Committee (GLC) to programs that were not 
GLC approved; this was done to determine the incidence and consequences of acquired resistance 
to second-line drugs (SLD)3 among MDR TB patients. Preliminary results suggest that acquired 
resistance to these drugs was lower in GLC approved programs. GLC approved projects also 
demonstrated higher cure rates, lower mortality, and lower treatment failure rates when compared 
with non-GLC approved projects.
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7DTBE continues to collaborate closely with the Pan-American Health Organization (PAHO) to 
develop policies and guidelines regarding national TB control in Latin American countries, 
while working with the Mexico National TB Program and U.S.-Mexico Border States to define 
challenges to TB control and improve continuity of care for persons who cross the U.S.-
Mexico border following a TB diagnosis.  DTBE is also working with CDC’s Division of Global 
Migration and Quarantine (DGMQ) to implement and evaluate technical instructions for 
overseas TB screening of immigrants and refugees, and provide advice on considerations for 
commercial travel restrictions.
Information about CDC’s TB programs and activities:
•	 Tuberculosis (TB) http://www.cdc.gov/tb/
•	 Drug-Resistant	Tuberculosis	(DR	TB)	http://www.cdc.gov/tb/topic/drtb/ 
•	 BOTUSA	(Botswana-USA	Partnership)	http://www.cdc.gov/botusa/
•	 Global	HIV/AIDS	http://www.cdc.gov/globalaids/
•	 Tuberculosis	Trials	Consortium	(TBTC):	http://www.cdc.gov/tb/topic/research/tbtc/default.htm 
•	 TB	Education	and	Training	Resources	Website:	www.findtbresources.org  
•	 TB-Related	News	Items:	www.cdcnpin.org/lyris/ui/listservs.aspx#journal 
Information about TB programs and activities at other USG agencies:
•	 USAID Tuberculosis http://www.usaid.gov/our_work/global_health/id/tuberculosis/
•	 NIAID	Tuberculosis	http://www.niaid.nih.gov/topics/tuberculosis/Pages/Default.aspx 
Information about World Health Organization programs and activities:
•	 Stop TB Department www.who.int/tb/en/
Improving Cross-Border Collaborations 
Additional Resources
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